• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HE4用于识别可能需要进行淋巴结切除术的子宫内膜样子宫内膜癌患者的效用。

Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.

作者信息

Dobrzycka Bozena, Mackowiak-Matejczyk Beata, Terlikowska Katarzyna Maria, Kinalski Maciej, Terlikowski Slawomir Jerzy

机构信息

Department of Obstetrics, Gynecology and Maternity Care, Medical University of Bialystok, Bialystok, Poland.

Department of Gynecologic Oncology, Bialystok Oncology Center, Bialystok, Poland.

出版信息

Adv Med Sci. 2016 Mar;61(1):23-7. doi: 10.1016/j.advms.2015.07.010. Epub 2015 Aug 9.

DOI:10.1016/j.advms.2015.07.010
PMID:26344910
Abstract

PURPOSE

The aim of the study was to establish whether preoperative serum levels of HE4 and CA125 could be a good predictor for lymphadenectomy in the early stage of endometrioid adenocarcinoma of the uterus.

MATERIAL AND METHODS

Preoperative serum HE4 and CA125 were measured in 78 postmenopausal patients treated surgically. The ROC curves were generated to determine the optimal cutoff values of HE4 and CA125 levels with optimum sensitivity and specificity for the prediction of lymphadenectomy.

RESULTS

Based on ROC curve, we found that the HE4 value of 78pmol/l is the best cutoff to identify candidates who may require lymphadenectomy with the sensitivity of 86.6% and the specificity of 67.2% (NPV=88.4% and PPV=51.2%). The area under the curve (AUC) equals 0.814 (95% CI=0.721-0.886). The cutoff level of CA125 that shows the prognostic indices is 26U/ml, with the sensitivity of 66.6% and the specificity of 61.2% (NPV=69.4% and PPV=44.3%). For CA125 the AUC amounts to 0.671 (95% CI=0.568-0.764). We also found a statistically significant difference, comparing HE4 and CA125 AUC (0.814 vs. 0.671, respectively, p<0.001). The combination of HE4 and CA125 established in our study as the cutoff point has the sensitivity of 81.2% and the specificity of 65.9% with NPV=83.4% and PPV=47.9%.

CONCLUSIONS

Our findings indicate that in the early stage of endometrioid endometrial cancer, HE4 can serve as a preoperative tool that can help to identify postmenopausal women who may require lymphadenectomy.

摘要

目的

本研究旨在确定术前血清HE4和CA125水平是否可作为子宫子宫内膜样腺癌早期淋巴结清扫术的良好预测指标。

材料与方法

对78例接受手术治疗的绝经后患者术前血清HE4和CA125进行检测。绘制ROC曲线以确定HE4和CA125水平的最佳临界值,用于预测淋巴结清扫术时具有最佳敏感性和特异性。

结果

基于ROC曲线,我们发现78pmol/l的HE4值是识别可能需要淋巴结清扫术患者的最佳临界值,敏感性为86.6%,特异性为67.2%(阴性预测值=88.4%,阳性预测值=51.2%)。曲线下面积(AUC)等于0.814(95%CI=0.721-0.886)。显示预后指标的CA125临界水平为26U/ml,敏感性为66.6%,特异性为61.2%(阴性预测值=69.4%,阳性预测值=44.3%)。对于CA125,AUC为0.671(95%CI=0.568-0.764)。我们还发现,比较HE4和CA125的AUC存在统计学显著差异(分别为0.814和0.671,p<0.001)。本研究确定的HE4和CA125联合临界值的敏感性为81.2%,特异性为65.9%,阴性预测值=83.4%,阳性预测值=47.9%。

结论

我们的研究结果表明,在子宫内膜样子宫内膜癌早期,HE4可作为一种术前工具,有助于识别可能需要淋巴结清扫术的绝经后女性。

相似文献

1
Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.HE4用于识别可能需要进行淋巴结切除术的子宫内膜样子宫内膜癌患者的效用。
Adv Med Sci. 2016 Mar;61(1):23-7. doi: 10.1016/j.advms.2015.07.010. Epub 2015 Aug 9.
2
HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.HE4 和 CA125 作为子宫内膜样腺癌术前淋巴结转移的风险分层因子:一项具有淋巴结状态组织学证据的队列回顾性研究。
Gynecol Oncol. 2021 Feb;160(2):514-519. doi: 10.1016/j.ygyno.2020.11.004. Epub 2020 Nov 16.
3
Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.血清人附睾蛋白4在预测上皮性卵巢癌手术预后较差方面优于癌抗原125。
Tumour Biol. 2016 Nov;37(11):14765-14772. doi: 10.1007/s13277-016-5335-0. Epub 2016 Sep 15.
4
The Utility of Preoperative Serum CA125 Combined with HE4 to Predict Lymph Node Metastasis in Endometrial Cancer.术前血清CA125联合HE4预测子宫内膜癌淋巴结转移的效用
Gynecol Obstet Invest. 2023;88(1):53-60. doi: 10.1159/000528851. Epub 2023 Jan 3.
5
Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging.人附睾蛋白4在子宫内膜癌中的预后价值及其在手术分期中的应用
J Obstet Gynaecol Res. 2015 Oct;41(10):1644-52. doi: 10.1111/jog.12764. Epub 2015 Jul 30.
6
Serum HE4 as a prognostic marker in endometrial cancer--a population based study.血清 HE4 作为子宫内膜癌的预后标志物——一项基于人群的研究。
Gynecol Oncol. 2014 Jan;132(1):159-65. doi: 10.1016/j.ygyno.2013.10.036. Epub 2013 Nov 6.
7
Preoperative serum CA125: a useful marker for surgical management of endometrial cancer.术前血清CA125:子宫内膜癌手术治疗的有用标志物。
BMC Cancer. 2015 May 12;15:396. doi: 10.1186/s12885-015-1260-7.
8
Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.血清人附睾蛋白4可在接受常规临床监测的患者中检测出复发性子宫内膜癌。
BMC Cancer. 2015 Feb 6;15:33. doi: 10.1186/s12885-015-1028-0.
9
Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.术前 ROMA 评分与上皮性卵巢癌患者临床分期的相关性。
Clin Transl Oncol. 2017 Oct;19(10):1260-1267. doi: 10.1007/s12094-017-1664-8. Epub 2017 Apr 25.
10
CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.在术前管理中被诊断为子宫内膜癌的捷克女性人群中 CA125 和 HE4 水平。
Anticancer Res. 2014 Jan;34(1):327-31.

引用本文的文献

1
Tumor biomarkers HE4 and CA125 alongside enhanced computed tomography imaging in assessing lymph node metastasis in endometrial cancer.肿瘤生物标志物HE4和CA125联合增强计算机断层扫描成像在评估子宫内膜癌淋巴结转移中的应用
Bioinformation. 2024 Nov 30;20(11):1453-1460. doi: 10.6026/9732063002001453. eCollection 2024.
2
Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features.血清CA125和HE4作为检测子宫内膜癌及相关高危特征的生物标志物。
Diagnostics (Basel). 2022 Nov 17;12(11):2834. doi: 10.3390/diagnostics12112834.
3
HE4 as a Biomarker for Endometrial Cancer.
人附睾蛋白4作为子宫内膜癌的生物标志物
Cancers (Basel). 2021 Sep 23;13(19):4764. doi: 10.3390/cancers13194764.
4
Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis.人附睾蛋白 4(HE4)在确定子宫内膜癌患者生存中的作用:一项荟萃分析。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820971660. doi: 10.1177/1533033820971660.
5
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients.RERT:一种预测子宫内膜癌患者宫外疾病的新回归树方法。
Sci Rep. 2017 Sep 5;7(1):10528. doi: 10.1038/s41598-017-11104-4.
6
Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients.血清HE4和MMP2水平在子宫内膜癌患者中的临床意义。
Onco Targets Ther. 2017 Jun 27;10:3169-3175. doi: 10.2147/OTT.S136750. eCollection 2017.
7
Analysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer.在子宫内膜样子宫内膜癌患者中,考虑选定风险因素对血清HE4和CA125水平的分析。
Contemp Oncol (Pozn). 2016;20(6):463-467. doi: 10.5114/wo.2016.65606. Epub 2017 Jan 12.
8
Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer.结合子宫内膜癌的分期、分级和组织学类型评估肿瘤标志物HE4和CA125的水平。
Prz Menopauzalny. 2016 Nov;15(3):133-137. doi: 10.5114/pm.2016.63059. Epub 2016 Nov 15.
9
Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.术前HE4、CA125及ROMA在附件区良恶性肿块鉴别诊断中的应用
J Ovarian Res. 2016 Jul 19;9(1):43. doi: 10.1186/s13048-016-0254-7.